Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker ARQT · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis NCT07916480 · Atopic Dermatitis, Atopic Dermatitis (AD) Roflumilast Cream 0.3%, Vehicle Cream | ARQT Arcutis Biotherapeutics, Inc. | Phase 3 | Recruiting was not yet recruiting | 415 | Apr 27, 2028 | Registry ↗ |
| Oct 23, 2026 | Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 NCT07453602 · Atopic Dermatitis (AD), Eczema ARQ-234, Placebo | ARQT Arcutis Biotherapeutics, Inc. | Phase 1 | Recruiting | 125 | Apr 2028 | Registry ↗ |
| Sep 9, 2026 | Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psorias… NCT04286607 · Chronic Plaque Psoriasis Topical roflumilast | ARQT Arcutis Biotherapeutics, Inc. | Phase 3 | Completed | 337 | Jan 22, 2024 | Registry ↗ |
| Aug 7, 2026 | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216) NCT04746911 · Psoriasis, Plaque Psoriasis ARQ-151 cream 0.3% | ARQT Arcutis Biotherapeutics, Inc. | Phase 2 | Completed | 10 | May 11, 2022 | Registry ↗ |
| May 22, 2026 | Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With… NCT07340216 · Psoriasis ARQ-154 Foam 0.3% | ARQT Arcutis Biotherapeutics, Inc. | Phase 1 | Completed | 22 | Apr 30, 2026 | Registry ↗ |
| Dec 23, 2025 | Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED) NCT04845620 · Atopic Dermatitis Eczema Roflumilast Cream 0.05%, Vehicle Cream | ARQT Arcutis Biotherapeutics, Inc. | Phase 3 | Completed | 652 | Jun 1, 2023 | Registry ↗ |
| Dec 23, 2025 | Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermati… NCT04804605 · Atopic Dermatitis Eczema ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% | ARQT Arcutis Biotherapeutics, Inc. | Phase 3 | Completed | 1,220 | May 28, 2024 | Registry ↗ |
| Dec 10, 2025 | Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic D… NCT06998056 · Atopic Dermatitis (Eczema) ARQ-151 cream 0.05% | ARQT Arcutis Biotherapeutics, Inc. | Phase 2 | Completed | 101 | Dec 4, 2025 | Registry ↗ |
| Jul 17, 2025 | Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) NCT05028582 · Scalp Psoriasis Roflumilast Foam 0.3%, Vehicle Foam | ARQT Arcutis Biotherapeutics, Inc. | Phase 3 | Completed | 432 | Jun 3, 2022 | Registry ↗ |
| Oct 9, 2024 | Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis NCT04773587 · Atopic Dermatitis Eczema Roflumilast Cream 0.15%, Vehicle Cream | ARQT Arcutis Biotherapeutics, Inc. | Phase 3 | Completed | 654 | Aug 30, 2022 | Registry ↗ |
| Oct 4, 2024 | Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II) NCT04773600 · Atopic Dermatitis Eczema Roflumilast Cream, Vehicle cream | ARQT Arcutis Biotherapeutics, Inc. | Phase 3 | Completed | 683 | Sep 29, 2022 | Registry ↗ |
| Jul 12, 2024 | Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo NCT04811131 · Vitiligo ARQ-252 cream 0.3%, ARQ-252 Vehicle cream | ARQT Arcutis Biotherapeutics, Inc. | Phase 2 | Terminated | 114 | Aug 9, 2021 | Registry ↗ |
| Jun 11, 2024 | Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis NCT04445987 · Seborrheic Dermatitis ARQ-154 | ARQT Arcutis Biotherapeutics, Inc. | Phase 2 | Completed | 408 | Nov 19, 2022 | Registry ↗ |
| Apr 5, 2024 | Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema NCT04378569 · Chronic Hand Eczema ARQ-252 cream 0.3%, ARQ-252 cream 0.1% | ARQT Arcutis Biotherapeutics, Inc. | Phase 1/2 | Completed | 230 | Feb 24, 2021 | Registry ↗ |
| Mar 12, 2024 | Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Derm… NCT04973228 · Seborrheic Dermatitis Roflumilast Foam, Vehicle Foam | ARQT Arcutis Biotherapeutics, Inc. | Phase 3 | Completed | 457 | Apr 6, 2022 | Registry ↗ |
| Dec 15, 2023 | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215) NCT04655313 · Psoriasis, Plaque Psoriasis ARQ-151 cream 0.3% | ARQT Arcutis Biotherapeutics, Inc. | Phase 2 | Completed | 20 | Jan 12, 2022 | Registry ↗ |
| Jul 24, 2023 | Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With… NCT04156191 · Atopic Dermatitis (Eczema) ARQ-151 cream 0.15%, ARQ-151 cream 0.05% | ARQT Arcutis Biotherapeutics, Inc. | Phase 1 | Completed | 101 | May 2, 2023 | Registry ↗ |
| Jul 3, 2023 | Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis NCT04091646 · Seborrheic Dermatitis Roflumilast Foam 0.3%, Vehicle foam | ARQT Arcutis Biotherapeutics, Inc. | Phase 2 | Completed | 226 | Aug 18, 2020 | Registry ↗ |
| Feb 13, 2023 | Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis NCT03916081 · Atopic Dermatitis Roflumilast Cream 0.05%, Roflumilast Cream 0.15% | ARQT Arcutis Biotherapeutics, Inc. | Phase 2 | Completed | 136 | Nov 4, 2019 | Registry ↗ |
| Dec 7, 2022 | Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis NCT04211389 · Chronic Plaque Psoriasis ARQ-151 0.3% cream, ARQ-151 vehicle cream | ARQT Arcutis Biotherapeutics, Inc. | Phase 3 | Completed | 442 | Nov 23, 2020 | Registry ↗ |
| Dec 7, 2022 | Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis NCT04211363 · Chronic Plaque Psoriasis Roflumilast 0.3% cream, Vehicle Cream | ARQT Arcutis Biotherapeutics, Inc. | Phase 3 | Completed | 439 | Nov 16, 2020 | Registry ↗ |
| Oct 26, 2022 | Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis NCT04128007 · Plaque Psoriasis Roflumilast foam 0.3%, Vehicle foam | ARQT Arcutis Biotherapeutics, Inc. | Phase 2 | Completed | 304 | Sep 23, 2020 | Registry ↗ |
| Sep 2, 2022 | Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis NCT03764475 · Plaque Psoriasis Roflumilast | ARQT Arcutis Biotherapeutics, Inc. | Phase 2 | Completed | 332 | Oct 8, 2020 | Registry ↗ |
| Sep 2, 2022 | The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis NCT03638258 · Plaque Psoriasis Roflumilast Cream 0.3%, Roflumilast Cream 0.15% | ARQT Arcutis Biotherapeutics, Inc. | Phase 2 | Completed | 331 | May 29, 2019 | Registry ↗ |
| Aug 4, 2022 | Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaq… NCT03392168 · Psoriasis ARQ-151 cream 0.5%, ARQ-151 cream 0.15% | ARQT Arcutis Biotherapeutics, Inc. | Phase 1/2 | Completed | 91 | May 2, 2018 | Registry ↗ |
| Aug 3, 2022 | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque… NCT04279119 · Plaque Psoriasis ARQ-151- cream 0.3% | ARQT Arcutis Biotherapeutics, Inc. | Phase 1 | Completed | 26 | Mar 25, 2021 | Registry ↗ |
26 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:28 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances